Published in Am J Pathol on March 01, 2003
Microarray based comparative genomic hybridisation (array-CGH) detects submicroscopic chromosomal deletions and duplications in patients with learning disability/mental retardation and dysmorphic features. J Med Genet (2004) 5.76
Comparative genomic hybridization-array analysis enhances the detection of aneuploidies and submicroscopic imbalances in spontaneous miscarriages. Am J Hum Genet (2004) 1.69
A group of genome-based biomarkers that add to a Kattan nomogram for predicting progression in men with high-risk prostate cancer. Clin Cancer Res (2009) 1.56
Genetic alteration and gene expression modulation during cancer progression. Mol Cancer (2004) 1.50
Gene expression patterns and gene copy number changes in dermatofibrosarcoma protuberans. Am J Pathol (2003) 1.49
Array-based comparative genomic hybridization from formalin-fixed, paraffin-embedded breast tumors. J Mol Diagn (2005) 1.40
Glioma test array for use with formalin-fixed, paraffin-embedded tissue: array comparative genomic hybridization correlates with loss of heterozygosity and fluorescence in situ hybridization. J Mol Diagn (2006) 1.16
High resolution oligonucleotide CGH using DNA from archived prostate tissue. Prostate (2007) 1.05
Expression analysis of imbalanced genes in prostate carcinoma using tissue microarrays. Br J Cancer (2006) 1.03
Deep clonal profiling of formalin fixed paraffin embedded clinical samples. PLoS One (2012) 1.03
DNA fragmentation simulation method (FSM) and fragment size matching improve aCGH performance of FFPE tissues. PLoS One (2012) 1.02
Genomic profiling of hormone-naïve lymph node metastases in patients with prostate cancer. Neoplasia (2006) 0.97
Limited tissue fixation times and whole genomic amplification do not impact array CGH profiles. J Clin Pathol (2006) 0.90
The zinc finger transcription factor ZKSCAN3 promotes prostate cancer cell migration. Int J Biochem Cell Biol (2012) 0.89
Comparison of chromosomal and array-based comparative genomic hybridization for the detection of genomic imbalances in primary prostate carcinomas. Mol Cancer (2006) 0.88
Genome-wide comparison of paired fresh frozen and formalin-fixed paraffin-embedded gliomas by custom BAC and oligonucleotide array comparative genomic hybridization: facilitating analysis of archival gliomas. Acta Neuropathol (2010) 0.87
Chromosomal and genetic imbalances in Chinese patients with rhabdomyosarcoma detected by high-resolution array comparative genomic hybridization. Int J Clin Exp Pathol (2014) 0.86
Whole genome amplification for array comparative genomic hybridization using DNA extracted from formalin-fixed, paraffin-embedded histological sections. J Mol Diagn (2009) 0.85
Recurrent genomic alterations in sequential progressive leukoplakia and oral cancer: drivers of oral tumorigenesis? Hum Mol Genet (2014) 0.84
An approach to the validation of novel molecular markers of breast cancer via TMA-based FISH scanning. J Mol Histol (2007) 0.83
Resolving tumor heterogeneity: genes involved in chordoma cell development identified by low-template analysis of morphologically distinct cells. PLoS One (2014) 0.82
Matrix-comparative genomic hybridization from multicenter formalin-fixed paraffin-embedded colorectal cancer tissue blocks. BMC Cancer (2007) 0.81
Detection of novel amplicons in prostate cancer by comprehensive genomic profiling of prostate cancer cell lines using oligonucleotide-based arrayCGH. PLoS One (2007) 0.79
Analysis of chromosome-11 aberrations in pulmonary and gastrointestinal carcinoids: an array comparative genomic hybridization-based study. Virchows Arch (2004) 0.77
High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays. Nat Genet (1998) 21.52
Assembly of microarrays for genome-wide measurement of DNA copy number. Nat Genet (2001) 11.06
Fully automatic quantification of microarray image data. Genome Res (2002) 3.47
Histologic grading of prostate cancer: a perspective. Hum Pathol (1992) 3.36
Evidence for a prostate cancer susceptibility locus on the X chromosome. Nat Genet (1998) 2.90
Abnormalities of chromosomes 3 and 8 in posterior uveal melanoma correlate with prognosis. Genes Chromosomes Cancer (1997) 1.87
Measurement of DNA copy number at microsatellite loci using quantitative PCR analysis. Cancer Res (2000) 1.82
High resolution deletion analysis of constitutional DNA from neurofibromatosis type 2 (NF2) patients using microarray-CGH. Hum Mol Genet (2001) 1.79
A genome screen of multiplex sibships with prostate cancer. Am J Hum Genet (2000) 1.51
Detection of multiple gene amplifications in glioblastoma multiforme using array-based comparative genomic hybridization. Lab Invest (2001) 1.50
Comparative genomic hybridization, allelic imbalance, and fluorescence in situ hybridization on chromosome 8 in prostate cancer. Genes Chromosomes Cancer (1994) 1.37
Prognostic value of p53 genetic changes in colorectal cancer. J Clin Oncol (1999) 1.20
Identification of genetic markers for prostatic cancer progression. Lab Invest (2000) 1.19
Universal linkage system: an improved method for labeling archival DNA for comparative genomic hybridization. Genes Chromosomes Cancer (1999) 1.13
Prognostic significance of molecular genetic aberrations on chromosome segment 11p15.5 in non-small-cell lung cancer. J Clin Oncol (2002) 1.12
Prostate cancer aggressiveness locus on chromosome 7q32-q33 identified by linkage and allelic imbalance studies. Neoplasia (2002) 1.11
Molecular cytogenetic analysis of prostatic adenocarcinomas from screening studies : early cancers may contain aggressive genetic features. Am J Pathol (2001) 1.11
Genome wide detection of oncogene amplifications in nasopharyngeal carcinoma by array based comparative genomic hybridization. Int J Oncol (2002) 1.10
Automated screening for genomic imbalances using matrix-based comparative genomic hybridization. Lab Invest (2002) 1.10
Identification and fine mapping of a region showing a high frequency of allelic imbalance on chromosome 16q23.2 that corresponds to a prostate cancer susceptibility locus. Cancer Res (2000) 1.06
Genetic alterations in prostate cancer cell lines detected by comparative genomic hybridization. Cancer Genet Cytogenet (1998) 1.05
Loss of heterozygosity at chromosome 16q in prostate adenocarcinoma: identification of three independent regions. Cancer Res (1997) 1.04
Loss of two new loci on chromosome 8 (8p23 and 8q12-13) in human prostate cancer. Int J Oncol (1999) 0.96
Allelic loss of 8p sequences in prostatic intraepithelial neoplasia and carcinoma. Urology (1997) 0.95
Allelic loss on chromosome 6Q in primary prostate cancer. Int J Cancer (1999) 0.94
Interphase cytogenetics of prostatic tumor progression: specific chromosomal abnormalities are involved in metastasis to the bone. Lab Invest (1997) 0.92
Genetic changes in clinically organ-confined prostate cancer by comparative genomic hybridization. Urology (2000) 0.88
Longitudinal evaluation of cytogenetic aberrations in prostatic cancer: tumours that recur in time display an intermediate genetic status between non-persistent and metastatic tumours. J Pathol (1998) 0.79
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell (2006) 27.36
Fine-scale structural variation of the human genome. Nat Genet (2005) 24.31
Distinct sets of genetic alterations in melanoma. N Engl J Med (2005) 17.26
Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell (2006) 16.05
Segmental duplications and copy-number variation in the human genome. Am J Hum Genet (2005) 13.33
Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst (2003) 11.27
Discovery of previously unidentified genomic disorders from the duplication architecture of the human genome. Nat Genet (2006) 10.36
Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature (2012) 8.13
Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol (2006) 7.76
Linkage disequilibrium and heritability of copy-number polymorphisms within duplicated regions of the human genome. Am J Hum Genet (2006) 7.70
End-sequence profiling: sequence-based analysis of aberrant genomes. Proc Natl Acad Sci U S A (2003) 7.70
A tiling resolution DNA microarray with complete coverage of the human genome. Nat Genet (2004) 7.68
Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability. Nature (2005) 7.24
Quality-of-life effects of prostate-specific antigen screening. N Engl J Med (2012) 7.21
Chromosome aberrations in solid tumors. Nat Genet (2003) 7.01
Array comparative genomic hybridization and its applications in cancer. Nat Genet (2005) 6.69
Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911. J Clin Oncol (2007) 6.23
TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. Am J Surg Pathol (2007) 6.09
Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res (2009) 5.68
A prediction-based resampling method for estimating the number of clusters in a dataset. Genome Biol (2002) 5.15
A comparison study: applying segmentation to array CGH data for downstream analyses. Bioinformatics (2005) 4.57
Active surveillance for low-risk prostate cancer worldwide: the PRIAS study. Eur Urol (2012) 4.48
Genomic microarrays in human genetic disease and cancer. Hum Mol Genet (2003) 4.15
Whole genome analysis of genetic alterations in small DNA samples using hyperbranched strand displacement amplification and array-CGH. Genome Res (2003) 4.10
Prostate specific antigen best practice statement: 2009 update. J Urol (2009) 3.95
The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int (2008) 3.94
A critical analysis of the tumor volume threshold for clinically insignificant prostate cancer using a data set of a randomized screening trial. J Urol (2010) 3.79
The connectome of a decision-making neural network. Science (2012) 3.70
Determinants of BRAF mutations in primary melanomas. J Natl Cancer Inst (2003) 3.65
Fully automatic quantification of microarray image data. Genome Res (2002) 3.47
Breast tumor copy number aberration phenotypes and genomic instability. BMC Cancer (2006) 3.34
Infectious complications and hospital admissions after prostate biopsy in a European randomized trial. Eur Urol (2012) 3.34
Interval cancers in prostate cancer screening: comparing 2- and 4-year screening intervals in the European Randomized Study of Screening for Prostate Cancer, Gothenburg and Rotterdam. J Natl Cancer Inst (2007) 3.26
A framework for the identification of men at increased risk for prostate cancer. J Urol (2009) 3.07
Rare amplicons implicate frequent deregulation of cell fate specification pathways in oral squamous cell carcinoma. Oncogene (2005) 2.99
Amplification of PVT1 contributes to the pathophysiology of ovarian and breast cancer. Clin Cancer Res (2007) 2.94
Outcomes of men with screen-detected prostate cancer eligible for active surveillance who were managed expectantly. Eur Urol (2008) 2.92
Complication rates and risk factors of 5802 transrectal ultrasound-guided sextant biopsies of the prostate within a population-based screening program. Urology (2002) 2.87
The relationship between prostate-specific antigen and prostate cancer risk: the Prostate Biopsy Collaborative Group. Clin Cancer Res (2010) 2.87
MC1R germline variants confer risk for BRAF-mutant melanoma. Science (2006) 2.84
Castration-resistant prostate cancer: from new pathophysiology to new treatment targets. Eur Urol (2009) 2.72
The actual value of the surgical margin status as a predictor of disease progression in men with early prostate cancer. Eur Urol (2006) 2.71
Contemporary role of androgen deprivation therapy for prostate cancer. Eur Urol (2011) 2.68
Prostate-specific antigen kinetics in clinical decision-making during active surveillance for early prostate cancer--a review. Eur Urol (2008) 2.66
Is there evidence of a relationship between benign prostatic hyperplasia and prostate cancer? Findings of a literature review. Eur Urol (2008) 2.65
Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma. J Clin Oncol (2007) 2.64
Reconstructing tumor genome architectures. Bioinformatics (2003) 2.61
Integrating data on DNA copy number with gene expression levels and drug sensitivities in the NCI-60 cell line panel. Mol Cancer Ther (2006) 2.55
Performance of the prostate cancer antigen 3 (PCA3) gene and prostate-specific antigen in prescreened men: exploring the value of PCA3 for a first-line diagnostic test. Eur Urol (2010) 2.55
Radical nephrectomy with and without lymph-node dissection: final results of European Organization for Research and Treatment of Cancer (EORTC) randomized phase 3 trial 30881. Eur Urol (2008) 2.55
Improving melanoma classification by integrating genetic and morphologic features. PLoS Med (2008) 2.52
Epigenome analyses using BAC microarrays identify evolutionary conservation of tissue-specific methylation of SHANK3. Nat Genet (2005) 2.51
International validation of a preoperative nomogram for prostate cancer recurrence after radical prostatectomy. J Clin Oncol (2002) 2.51
Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection. Eur Urol (2010) 2.47
High-resolution genomic and expression analyses of copy number alterations in breast tumors. Genes Chromosomes Cancer (2008) 2.46
Screening for prostate cancer: results of the Rotterdam section of the European randomized study of screening for prostate cancer. Eur Urol (2013) 2.43
Large-scale variation among human and great ape genomes determined by array comparative genomic hybridization. Genome Res (2003) 2.41
Evaluation of paired-end sequencing strategies for detection of genome rearrangements in cancer. PLoS Comput Biol (2008) 2.40
Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer. Cancer Res (2010) 2.39
Array-based comparative genomic hybridization for genome-wide screening of DNA copy number in bladder tumors. Cancer Res (2003) 2.34
Comparative genomic hybridization. Annu Rev Genomics Hum Genet (2005) 2.34
Regional copy number-independent deregulation of transcription in cancer. Nat Genet (2006) 2.33
Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies. Ann Intern Med (2008) 2.33
Prostate-specific antigen velocity for early detection of prostate cancer: result from a large, representative, population-based cohort. Eur Urol (2009) 2.31
Bladder cancer outcome and subtype classification by gene expression. Clin Cancer Res (2005) 2.29
High-resolution array comparative genomic hybridization of chromosome arm 8q: evaluation of genetic progression markers for prostate cancer. Genes Chromosomes Cancer (2005) 2.25
Multiparametric magnetic resonance imaging in prostate cancer: present and future. Curr Opin Urol (2008) 2.23
The effect of study arm on prostate cancer treatment in the large screening trial ERSPC. Int J Cancer (2010) 2.15
High-resolution analysis of DNA copy number alterations in colorectal cancer by array-based comparative genomic hybridization. Carcinogenesis (2004) 2.13